Skip to content
Medical Health Aged Care

Approval and funding for the future of paediatric palliative care

Palliative Care Australia 2 mins read

Paediatric palliative care and its important role within the health sector has been recognised with new funding from the Australian Department of Health and Aged Care. 

The $1.25 million for Palliative Care Australia’s ‘Shaping the Future of Paediatric Palliative Care’ project builds on a growing awareness that palliative care for infants, children, young people, and their family’s requires a specialised focus.   

“This investment by the Health Minister, Mark Butler, is timely because it means we can build on the hard work of the last three years in developing the Paediatric Palliative Care National Action Plan,” says Camilla Rowland, Chief Executive Officer, Palliative Care Australia (PCA). 

“The Health Department has just given the final sign off on the Action Plan, so this new funding means we can get to work on some of its insights. 

“The Action Plan is a roadmap for a national approach that provides guidance and direction on key priorities to improve outcomes for infants, children and young people living with a life-limiting condition. 

“The strength of the Action Plan is the deep input patients, families, the work force, and other stakeholders have had in developing the final document,” Ms Rowland says. 

The Action Plan was prepared by PCA in partnership with Paediatric Palliative Care Australia and New Zealand, with funding from the Australian Government. 

“We are planning to launch the plan very soon and have it easily available to palliative care services and the wider health community,” Ms Rowland says. 

“This is a first of its kind for Australia and there is a real momentum behind it.” 

With the Action Plan approved, PCA is now fully scoping what the ‘Shaping the Future of Paediatric Palliative Care’ project looks like. 

“To receive this new funding now means we don’t lose any of the knowledge, contacts, or energy of the Action Plan – we can build on it and grow its impact for the precious people it seeks to serve,” Ms Rowland says. 

“Drawing on the voice of lived experience will again be really important to our work.” 

You can view and download the Paediatric Palliative Care National Action Plan HERE.

A snapshot of paediatric palliative care: 

  • 28,976 children and young people (0-21 years) were estimated to be living with life-limiting conditions in Australia in 2021. Note: The actual number remains unknown due to a lack of readily available national data. The evidence to support planning and service delivery is limited 
  • Children under the age of 1 year are the biggest cohort of patients (around 300 children per 10,000 people), followed by 4-6yrs, 1-3yrs, 19-21yrs, 16-28yrs, 13-15yrs, 10-12yrs, and 7-9yrs (all between 25 and 40 children or young people per 10,000 people). Bowers A et al. (2020) 
  • 38% of life-limiting conditions in children and young people are cancer related. Bowers A et al. (2020) 
  • Aboriginal and Torres Strait Islander People have higher prevalence of paediatric life-limiting conditions. Bowers A et al. (2020) 
  • The proportion of children with a life-limiting condition who have complex needs is estimated to be around 38%. Palliative Care Australia (2018) 
  • Unlike adult patients, paediatric palliative care is generally delivered over a longer time frame – on average, it’s about 40% longer than for adults. Connor SR et al. (2017) 

Contact details:

Ian Campbell

P: 0417 482 171

E: [email protected]

Media

More from this category

  • Medical Health Aged Care
  • 21/01/2026
  • 06:10
Amoeba

Gold medal winner at SIVAL, Amoéba displays its ambitions for its biocontrol solution

Chassieu, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Chassieu (France), 20 January 2026 – 6:00 pm -Amoéba (FR0011051598 - ALMIB), industrial greentech specialised in the development of natural microbiological solutions based on the patented use of amoebae, recaps its recent participation in SIVAL (International Exhibition of Plant Production Techniques) in Angers (France). During this leading European and global event for the crop industry, Amoéba won the gold medal in the SIVAL Innovation 2026 Competition for its biocontrol solution and announced, together with its partner Koppert, the commercial launch in 2026 of its biocontrol solution for treating vineyards and vegetable crops as…

  • Medical Health Aged Care
  • 21/01/2026
  • 00:41
Crown Bioscience

Crown Bioscience San Diego Laboratory Achieves CAP Accreditation, Building on CLIA Certification to Expand Clinical-Grade Capabilities

SAN DIEGO–BUSINESS WIRE– Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced that its San Diego laboratory…

  • Contains:
  • Medical Health Aged Care
  • 20/01/2026
  • 10:00
Monash University

Monash University researcher appointed to the board of the Asthma Council

The National Asthma Council Australia (NAC) has announced the appointment of Pharmaceutical Society of Australia (PSA) nominee Dr Amanda Cross to the board. Dr Cross is a clinical pharmacist and Senior Research Fellow at Monash University's Centre for Medicine Use and Safety, within the Monash Institute of Pharmaceutical Sciences (MIPS). Her work focuses on medicine safety and quality use of medicines for older adults. She is particularly interested in the role of healthcare professionals working as knowledge brokers to support the uptake of research evidence and guidelines into clinical practice. Evidence-to-practice gaps are a major barrier to avoiding medication-related harm.…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.